Research programme: drugs targeting solute carrier proteins - Solgate GmbH
Latest Information Update: 28 Mar 2025
At a glance
- Originator Solgate
- Class Antineoplastics; Small molecules
- Mechanism of Action Solute carrier protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Metabolic disorders; Neurological disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Cancer in Austria
- 28 Mar 2025 No recent reports of development identified for research development in Metabolic-disorders in Austria
- 28 Mar 2025 No recent reports of development identified for research development in Neurological-disorders in Austria